Beam Therapeutics
BEAM

$33.14

3.02%

Market Cap: 2.73B

About: Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Employees: 436

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 13 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 3 (+2) [Q1 2024]

160% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 20

70% more repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 46

23% more capital invested

Capital invested by funds: $1.88B [Q4 2023] → $2.31B (+$437M) [Q1 2024]

17% more funds holding

Funds holding: 183 [Q4 2023] → 215 (+32) [Q1 2024]

1.2% more ownership

Funds ownership: 84.54% [Q4 2023] → 85.74% (+1.2%) [Q1 2024]

53% less call options, than puts

Call options by funds: $13.8M | Put options by funds: $29.1M

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$33

0%

upside

Avg. target

$49

48%

upside

High target

$80

141%

upside

7 analyst ratings

4 positive

57%

3 neutral

43%

0 negative

0%

HC Wainwright & Co. Patrick Trucchio	141%upside $80	Buy Initiated	23 Jul 2024
Barclays Gena Wang	0%downside $33	Equal-Weight Maintained	8 May 2024
Wedbush David Nierengarten	72%upside $57	Outperform Reiterated	23 Apr 2024
BMO Capital Kostas Biliouris	72%upside $57	Outperform Maintained	27 Mar 2024
Barclays Gena Wang	27%upside $42	Equal-Weight Maintained	28 Feb 2024

See Analyst Rankings

Financial journalist opinion

Based on 13 articles about BEAM published over the past 30 days

Zacks Investment Research

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?

Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?

Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40

Speculators seeking a big pop over the next few months should consider a high-risk, high-reward position in Beam Therapeutics (NASDAQ: BEAM ). According to its public profile, Beam specializes in precision genetic medicines, which is a growing and viable market.

Trade of the Day: Buy Beam Therapeutics Call Options as BEAM Stock Heads to $40

3 Gene Editing Stocks Shaping the Future of Medicine

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

3 Gene Editing Stocks Shaping the Future of Medicine

Zacks Investment Research

Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines

Beam Therapeutics' (BEAM) current chief financial officer, Terry-Ann Burrell, is set to step down from her role on Aug 9. The stock falls 4.7%.

Beam Therapeutics' (BEAM) CFO to Step Down, Stock Declines

Beam Therapeutics Announces Transition of Chief Financial Officer

CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.

Beam Therapeutics Announces Transition of Chief Financial Officer

Zacks Investment Research

Here's Why You Should Invest in Beam Therapeutics (BEAM) Now

Here, we discuss why investing in Beam Therapeutics (BEAM) stock now may be a prudent move.

Here's Why You Should Invest in Beam Therapeutics (BEAM) Now

Zacks Investment Research

Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?

Beam Therapeutics (BEAM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Beam Therapeutics (BEAM) Upgraded to Buy: What Does It Mean for the Stock?

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024

Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks.

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024

3 Stocks With the Potential to 10X Your Money

In recent months, markets have reached new record highs, signaling that high-growth potential stocks offer opportunities to multiply earnings. The number of high-wealth individuals in the U.S. grew substantially last year alongside the stock market, partly due to notable gains among artificial intelligence (AI) stocks.

3 Stocks With the Potential to 10X Your Money

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.

FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals

See News Rankings